Back to search results

Vancomycin for Primary Sclerosing Cholangitis and Biliary Atresia

This study is testing whether oral vancomycin, an antibiotic, can effectively treat Primary Sclerosing Cholangitis (PSC) and Biliary Atresia (BA) in their early stages. Researchers also want to understand how vancomycin affects the bacteria in your gut (intestinal microbial communities) and how these bacteria interact with your body. You may be able to join if you have PSC, BA, a chronic intestinal disorder, or are having an endoscopy, and are between 2 weeks and 40 years old. The main goal is to see if vancomycin helps improve these conditions after 3 months. The study is currently unclear on its recruitment status and plans to enroll 200 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 200 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary benefit of oral vancomycin therapy will be measured at 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02137668

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

Recruiting
PHASE1Ages 2–40InterventionalTreatment
Sacramento Pediatric Gastroenterology
~200 participants
Updated 2016-11-15 on ClinicalTrials.gov
What's tested:Oral Vancomycin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis and Biliary Atresia
Measured over 3 months

Conditions

Primary Sclerosing Cholangitis
Biliary Atresia

Explore related trials

Biliary AtresiaIntestinal DisorderPrimary Sclerosing Cholangitis

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Yinka Davies, M.D. · PRINCIPAL_INVESTIGATOR · Sacramento Pediatric Gastroenterology

Who to contact

Yinka Davies, MD
916-332-1244
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Persons who have primary sclerosing cholangitis, biliary atresia, a chronic intestinal disorder or who are undergoing upper or lower endoscopy.
Persons who have primary sclerosing cholangitis or biliary atresia who are good candidates for vancomycin therapy.

Exclusion

Patients that have taken antibiotics and/or immunomodulators within the last 3 months will be excluded as this will alter the original bacterial flora.
Females who are pregnant may not participate.

What this trial measures

  • Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis and Biliary Atresia3 months

    Blood tests, imaging studies and/or liver biopsy changes before and while on oral vancomycin will determine the benefit of the treatment.